Dr. James Berenson helps patients understand new FDA recommendations regarding the use of lenalidomide (Revlimid) and a study from Sweden regarding increased risk of blot clots for myeloma patients. Dr. Berenson also previews the topics that he believes will be important for patients at the upcoming ASCO conference.
Tag Archives: Revlimid
James R. Berenson, MD
President and CEO - James R. Berenson, MD, Inc.
Medical & Scientific Director - Institute for Myeloma
& Bone Cancer Research (IMBCR)
Chief Executive Officer - Oncotherapeutics
- Combined TRAF6 Targeting and Proteasome Blockade has Anti-tumor and Anti-bone Resorptive Effects
- Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients
- Outcomes in Multiple Myeloma Patients Evaluated
- Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib
- Soluble B-Cell Maturation Antigen Mediates Tumor-Induced Immune Deficiency in Multiple Myeloma
- Combined TRAF6 Targeting and Proteasome Blockade has Anti-tumor and Anti-bone Resorptive Effects
- The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo
- Oncology CRO Oncotherapeutics Presents at ASH 2011 Annual Meeting
- Understanding Myeloma News About Secondary Cancers and Clotting
-
Dedication of “Determination”
May 28, 2012
0 Comments